It has, and Pfizer and Biontec in particular have scaled up production quite effectively (delivering more than originally committed). AstraZeneca is fairly dramatically behind on production (delivered about 33% of commitments in the EU so far), and at this point it feels like the European Commission has basically abandoned it; its contract is apparently not getting renewed.